* Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.
0.05% sodium azide
-20° C, Avoid Freeze/Thaw Cycles
Product Specific Information
PA3-105 detects N-methyl-D-aspartate (NMDA) receptor type 2B.
PA3-105 has been used successfully in Western blot, ELISA, immunoprecipitation, immunohistochemistry, and immunocytochemistry procedures. In Western blot analysis of rat brain synaptic membranes this antibody detects a ~180 kDa protein representing NMDA receptor type 2B.
The PA3-105 immunogen is a synthetic phosphopeptide corresponding to residues (C) G(1328) R F M D G S P Y(p) H(1337) of rat NMDA receptor 2B.
N-methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels that have a high permeability to calcium found in the central nervous system. The receptor consists of a number of distinct ligand binding domains, and the presence of both glutamate and glycine are required for full activation of the channel. Within the channel there is also a binding site for magnesium, which, when occupied, propagates a voltage-dependent channel block. Other binding sites are also found in the receptor, including a zinc-binding site and an inter-channel site that binds specific channel blockers such as phencyclidine (PCP) and related compounds. The NMDA receptor has been demonstrated to play an essential role in long-term potentiation (LTP), a phenomenon that has been implicated to be the basis for learning and memory. The influx of calcium as a result of channel activation is thought to be responsible for neuronal plasticity and glutamate neurotoxicity.
A number of different NMDA receptor subunits have been cloned that may possess different functional and localization properties. The NMDA-R1 subunit (NR1) is expressed throughout the brain, while the NMDA-R2 subunits (NR2A, NR2B, NR2C, and NR2D) have a more specific localization pattern. The NMDA receptor subunits differ also in glycine sensitivity, the relative strength of the magnesium channel block, and their respective agonist-dependent deactivation time. Differential splicing of three distinct exons of NR1 generates eight NR1 splice variants. These exons encode a 21 amino acid N-terminal domain (N1) and two 21 amino acid C-terminal domains (C1 and C2, respectively). Splicing out the C2 cassette eliminates a stop codon, generating a new 22 amino acid C-terminal domain (C2'). These splice variants have differing patterns of expression.
NMDA Receptor 2B Antibody (PA3-105) in IF Grin2b-Antibody-PA3-105-Immunofluorescence-IF.jpg
Immunofluorescence with anti-NMDA Receptor 2B Polyclonal Antibody (PA3-105)